Online inquiry

IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ68MR)

This product GTTS-WQ68MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets H1-0 gene. The antibody can be applied in Glioblastoma multiforme (GBM) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_005318.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3005
UniProt ID P07305
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ68MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1564MR IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ACE-041
GTTS-WQ14072MR IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA REGN-3918
GTTS-WQ394MR IVTScrip™ mRNA-Anti-TYRP1, 20D7S(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 20D7S
GTTS-WQ2322MR IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ALXN6000
GTTS-WQ38MR IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 2857916
GTTS-WQ4163MR IVTScrip™ mRNA-Anti-LAG3, BI-754111(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BI-754111
GTTS-WQ12730MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA OMP-305B83
GTTS-WQ5433MR IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CD74-DOX (ADC)
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW